Intravitreal Conbercept For Branch Retinal Vein Occlusion induced Macular Edema: One Initial Injection Versus Three Monthly Injections

CURRENT STATUS: UNDER REVIEW

BMC Ophthalmology  BMC Series

Xi Chen
Nanjing University of Chinese Medicine

Tianming Hu
Nanjing University of Chinese Medicine

Jing Zuo
Nanjing University of Chinese Medicine

Hao Wu
Nanjing University of Chinese Medicine

Zehao Liu
Nanjing University of Chinese Medicine

Yaxin Zhan
Nanjing University of Chinese Medicine

Ying Xia
Nanjing University of Chinese Medicine

Jing Wang
Nanjing University of Chinese Medicine

Wei Wei
Affiliated Hospital of Nanjing University of Chinese Medicine

13951776603@163.com Corresponding Author

DOI:
10.21203/rs.3.rs-20288/v1

SUBJECT AREAS
Ophthalmology

KEYWORDS
Branch retinal vein occlusion, Macular edema, Conpercept, PRN
Abstract
Objective To compare the efficacy of one initial intravitreal injection of conbercept (IVC) versus three monthly IVCs in patients with macular edema (ME) after branch retinal vein occlusion (BRVO). Both options were followed by a pro re nata (PRN) retreatment regimen.
Methods This study retrospectively investigated and followed 49 patients with acute ME secondary to BRVO for over a year. 24 subjects received one initial injection (1+PRN group); while, 25 received three monthly injections (3+PRN group). The functional and anatomic outcomes were assessed during each follow-up.
Results The general characteristics of the 49 subjects were as follows: mean [SD] age, 56.12 [12.54] years; 28 [57.1%] female; 30 [61.2%] non-ischemic form. Both groups showed a stable gain in visual acuity (VA) with similar logMAR (mean ± SD) (1+PRN group 0.308±0.431, 3+PRN group 0.345±0.366) during the first 12 months. Additionally, both groups exhibited a significant reduction in central foveal thickness (CFT) with no statistically significant difference between them (1+PRN group 220.5 μm ±219.9 μm , 3+PRN group 230.2 μm ±220 μm ). Both treatment groups had similar improvements in logMAR and anatomic outcomes over time. The stratified analysis showed that patients with the non-ischemic form and those with the ischemic form had similar improvements in VA (0.351±0.387 VS 0.289±0.417, P =0.601) during the 12 months follow-ups. The number of injections was lower in the 1+PRN group (4.0±1.7) than in the 3+PRN group (4.6±1.2) ( P =0.155). No adverse effects or unexpected safety issues were reported in either group.
Conclusions Conbercept yielded stronger improvements in VA and CFT among patients with BRVO induced ME independent of their retinal ischemia status. The results showed that the 3+PRN regimens do not lead to better functional outcomes or lower treatment needs in clinical practice as compared to the 1+PRN regimen.
Introduction
Retinal vein occlusion (RVO) is the second most common retinovascular disease after diabetic retinopathy, resulting in severe visual dysfunction among several patients worldwide [1]. A previously conducted pooled analysis showed that branch retinal vein occlusion (BRVO) (0.44%) had a higher
prevalence than central retinal vein occlusion (CRVO) (0.08%) [2]. Clinically, observations of BRVO by fundus photography and fluorescein angiography are often indicative of retinovascular hemorrhage, dilated and tortuous retinal vessels, cotton-wool spots, and retinal non-perfusion (NP).

Vascular endothelial growth factor (VEGF), through its complex interactions with vascular endothelial cell proliferation and vascular permeability, plays a key role in the pathogenesis of BRVO induced macular edema (ME) [3] and neovascularization[4, 5]. It has been well established that retinal nonperfusion and hemorrhages due to vascular occlusion can lead to an increase in VEGF production, hence exacerbating ME and ischemia[6]. In recent years, the use of anti-VEGF inhibitors has dramatically increased, making them the standard of care for BRVO-ME in many countries[7]. Studies have shown that intravitreal injections of anti-VEGF inhibitors are more effective in resolving ME and improving the best-corrected visual acuity (BCVA) as compared to other treatments such as bevacizumab[8], ranibizumab[7], or aflibercept[9]. Conpercept (KH902; Chengdu Kanghong Biotech Co., Ltd., Sichuan, China) has been approved by the Chinese Food and Drug Administration for the treatment of RVO induced ME. It is a fusion protein that contains the extracellular domain 2 of VEGF receptor 1 and extracellular domains 3 and 4 of VEGF receptor 2 combined with the Fc portion of the human immunoglobulin G1. Previous studies have also shown that a regular pro re nata (PRN) use of VEGF blockade in RVO seems to have a significant and lasting effect on VA gain [10]. YUKO MIWA et al. [11] showed that there are no significant differences in functional outcomes between BRVO induced ME patients treated with a single monthly PRN injection of ranibizumab and those with three monthly PRN injections. The efficacy and safety of 3 monthly PRN injections of conbercept for the treatment of ME after RVO have been previously established by FALCON et al.[12]. Therefore, we evaluated the benefits and compared the visual and anatomical outcomes of a single monthly injection versus three monthly injections of conbercept in the treatment of ME after BRVO.

Materials And Methods
Participants
This retrospective study analyzed data from 49 patients with a confirmed diagnosis of macular edema after BRVO and a history of intravitreal injections of conbercept. The data in this study was collected
from August 2017 to August 2019. All data originated from the Department of Ophthalmology, Jiangsu Provincial Hospital of Chinese Medicine (Nanjing, China). The purpose of the treatment and potential adverse effects were thoroughly explained, and all subjects signed informed consent before treatment initiation.

The eligibility criteria included the followings: patients should be at least 18 years of age; have decreased visual acuity; should have BRVO with retinal edema, and a central foveal thickness CFT > 250 µm as assessed by optical coherence tomography (OCT). The exclusion criteria were: patients with their last intravitreal anti-VEGF treatment being within less than three months; patients with a history of ocular surgery; patients with an ocular disease such as diabetic retinopathy, senile cataract, and age-related macular degeneration, that significantly affected the BCVA; patients with a history of interventions or neovascularization (NV) before the study period; patients with advanced glaucoma, intraocular pressure (IOP) > 22 mm Hg.

Treatment
The study sample collected divided into either the 1 + PRN group or the 3 + PRN group. 24 eyes received a single monthly intravitreal injection of conbercept, and 25 eyes received three monthly intravitreal injections of conbercept. An initial intravitreal conbercept injection was administered at day one, followed by a continuous monthly treatment until stabilization of BCVA. The retreatment criteria, according to the RPN scheme, were: PRN injections were continued upon BCVA loss, ME, or evidence of serious foveal retinal detachment on OCT sections.

Assessments
The Early Treatment Diabetic Retinopathy Study (ETDRS) was used to evaluate temporal changes in best-corrected VA between the two groups. The secondary outcome was defined as pre and post-treatment mean changes in central retinal thickness (HD-OCT (Zeiss, Germany)) and is reflective of treatment response. The CFT was assessed by HD-OCT measurements between the vitreoretinal interface and the anterior boundary of the retinal pigment epithelium. Additional outcomes were defined as follows: the investigation and evaluation by fluorescein fundus angiography (FFA, Heidelberg, Germany) of ischemic or non-ischemic BRVO and retinal circulation; the analysis and
quantification of the number of injections during the 12 months follow-up. Safety assessments, including ocular, systemic adverse events (AEs), serious AEs (SAEs), and their correlation with the treatment, as well as injection procedures, were carried out at each follow-up.

Statistical analysis
All statistical analyses were carried out using SPSS 20.0 (SPSS, Inc., Chicago, IL, USA). Quantitative data were presented as mean ± SD. VA measurements were converted to a logarithm of the minimum angle of resolution (logMAR) for statistical analysis. A paired t-test was used to analyze changes in VA as well as CFT within each group. Meanwhile, an unpaired t-test was used to compare the two parametric data between treatment groups. Differences in distributions were analyzed through chi-square tests. A P value < 0.05 was considered statistically significant.

Results
Study Population and Baseline Characteristics
Among the 49 participants in this study, 24 (48.98%) received a single initial IVC, and 25 (51.02%) received three monthly IVC. The baseline characteristics of each study group are summarized in Table 1. There were similarities in patient demographics and baseline ocular characteristics between the two groups. 30 eyes were classified as non-ischemic, and 19 eyes were classified as ischemic after FAA. All patients in this study are Asian.

Change in Best-corrected visual acuity and central foveal thickness
Both groups showed significant improvement in mean BCVA and reduction in mean CFT one month after the initiation of the treatment. Figure 1 shows significant improvements in overall mean BCVA 0.327 ± 0.396 between the baseline values and the 12 months follow-up in all treated eyes (P < 0.001). The 12 months follow-up indicated a significant reduction in overall mean CFT (225.5 µm ± 217.7 µm) of all treated eyes (P < 0.001). Figure 2 indicates an increase in means BCVA (0.308 ± 0.431 logMAR and 0.345 ± 0.366 logMAR) at 12 months in the 1 + PRN and the 3 + PRN groups, respectively. No statistically significant difference was seen between the two groups (p = 0.744). Both groups showed a significant decrease in means CFT (220.5 µm ± 219.9 µm and 230.2 µm ± 220 µm) at the 12 months follow-up, with no statistically significant difference between them (p = 0.879). A
secondary analysis indicated that CFT tended to be smaller and VA to be better in the 3+PRN group compared to the 1+PRN group in the 12 months follow-up. Additionally, the analysis indicated that the choice of the treatment regimen was no association with the final BCVA and final CFT (P > 0.05).

**Stratified Analysis of Best-corrected visual acuity and Central Foveal Thickness**

We stratified patients according to baseline FFA examinations. Patients with a peripheral capillary nonperfusion greater than five disc areas were categorized as ischemic BRVO (n = 19 eyes), and the remaining were classified as non-ischemic BRVO (n = 30 eyes). Figure 3 shows the mean CFT and the logMAR VA in each subgroup. The findings indicated significant improvements in VA (0.351 ± 0.387 logMAR in the non-ischemic and 0.289 ± 0.417 logMAR in the ischemic subgroups) at the 12 months follow-up. However, no statistically significant difference was observed between the two subgroups (P = 0.601). Even so, the non-ischemic subgroup exhibited better mean VA than the ischemic subgroup during the entire observation period. Similarly, a significant decrease in CFT (226.6 µm ± 240.4 µm in the non-ischemic subgroup and 223.6 µm ± 182.2 µm in the ischemic subgroup) was seen at the 12 months follow-up. Nevertheless, there was no statistically significant difference between the two subgroups (P = 0.963).

**Number of pro re nata Conbercept Injections**

Over the 12 postoperative months, the mean ± SD number of conbercept injections in patients receiving the 1+PRN and the 3+PRN (range 2–9) were 4.0 ± 1.7 and 4.6 ± 1.2, respectively. There was no significant difference between the two groups (P = 0.155, Table 1). The total number of PRN injections was significantly associated with a shorter duration until the first PRN injection in both groups (R = -0.489, P = 0.003; R = -0.452, P = 0.008, respectively, Fig. 4B).

**Safety assessments**

Adverse events of interest were rare during the entire observation period, and all patients in the study did not show significant side effects.

**Discussion**

Although the traditional PRN treatment regimens have demonstrated their usefulness in the treatment of BRVO, the debate of whether their efficacy outways the resultant patient burden on the health care system remains. In recent years, anti-VEGF intravitreal therapy has been extensively used
for the treatment of ME associated with BRVO. This study was conducted to assess the effects of monthly intraocular injections of conbercept through a span of 12 months. According to our results, even though the overall mean number of injections was 4.4 ± 1.5, the use of conbercept with PRN regimens yielded favorable outcomes in visual acuity and steady reductions in ME.

The overall sample is comprised of 49 eyes, with 24 eyes allocated to the 1 + PRN group and 25 eyes to the 3 + PRN group. The results showed that VA and CFT at baseline were not significantly different between the two treatment groups. Further analysis indicated that the 1 + PRN group showed significant improvement in mean logMAR VA (from 0.772 ± 0.382 at baseline to 0.464 ± 0.285 at month 12 (p < 0.001)) at 12 months follow-up. Similarly, the 3 + PRN group also exhibited improvements in mean logMAR VA (from 0.731 ± 0.456 at baseline to 0.386 ± 0.311 at month 12 (p < 0.001)) during the last follow-up. Additionally, both groups showed significant decrease in mean CFT (from 522.3 μm ± 211.2 μm at baseline to 301.8 μm ± 98.9 μm at month 12 (p < 0.001) for the 1 + PRN group and from 519.2 μm ± 202.8 μm at baseline to 289.1 μm ± 52.2 μm at month 12 (p < 0.001) for the 3 + PRN group, respectively) during the last follow-up. There was no significant difference in the final mean VA or final CFT between the two regimens. However, patients tended to have greater CFT and worse VA in the 1 + PRN group as compared to the 3 + PRN group during the observation period (although the changes of VA and CFT were not statistically significant between the two groups). Moreover, lower fluctuation of mean logMAR VA and CFT were observed in patients belonging to the 3 + PRN group at the three months follow-up. ZUHUA SUN et al.[12] previously reported that the differences in mean VA values between BRVO and CRVO groups were relatively small (17.83 ± 10.89 letters VS 14.23 ± 11.74), indicating that IVC is generally safe and effective. Thus, taking into account our findings, it is clear that the reductions in mean CFT and gains in mean VA in the 1 + PRN regimen are almost similar to those of the 3 + PRN regimen. A recent study[13] with similar study designs and using PRN treatment protocols also had similar outcomes.

As expected, the total number of injections per eye in the 1 + PRN group (4.0 ± 1.7) was slightly lower than that in the 3 + PRN group (4.6 ± 1.2) (P = 0.155). Both regimens showed similar efficacy. Our study not only included patients with PRN treatment regimens but also those with non-ischemic
or ischemic BRVO induced ME. We observed higher injection numbers on average in eyes belonging to the ischemic subgroup (4.5 ± 1.7) as compared to those in the non-ischemic subgroup (4.3 ± 1.3, P = 0.635). The baseline data showed that compared to the 30 non-ischemic eyes, the 19 eyes in the ischemic subgroup had slightly worse CFT and VA values. However, the difference was not statistically significant. This may be partially due to the correlation between ischemia and greater CFT, as well as poorer VA[14]. Stratified analysis of the non-ischemic subgroup showed a rapid reduction in ME and significant improvement of BCVA at month 12 (from 0.735 ± 0.365 at baseline to 0.384 ± 0.238, p < 0.001). In contrast, the analysis of the ischemic subgroup indicated a reduction in ME with slow improvement in VA at month 12 (from 0.776 ± 0.5 at baseline to 0.487 ± 0.373, P = 0.007).

Additionally, VA tended to be lower in the ischemic subgroup as compared to the non-ischemic one. Consequently, the findings suggested that these factors are closely associated with the functional outcome.

It is worth noting that the novelty of this study is that it provides crucial information on anti-VEGF therapy and shows that it can achieve a promising outcome and significantly improve VA and CFT regardless of the nature of the ME (non-ischemic or ischemic). In this study, 10 of the ischemic subgroup patients received conbercept + laser treatments. Interestingly, The BRIGHTER study has previously shown that the addition of laser does not lead to better functional outcomes or lower treatment needs[15]. In their study, Ramin Tadayoni et al. compared changes in BCVA outcome and ranibizumab injections between the ranibizumab + laser and the ranibizumab monotherapy groups. They concluded that there were no significant differences in VA and numbers of ranibizumab injections between groups (11.3 vs. 11.4). Another recent clinical trial [16] demonstrated that the trend of improvement in VA and reduction of CMT observed during conbercept usage for the treatment of ME secondary to BRVO were similar to those obtained with ranibizumab.

In summary, our study reported findings on the efficacy of anti-VEGF treatment and provided additional data on PRN protocols in patients with BRVO-ME. It showed that there were no significant differences in outcomes between the 1 + PRN and the 3 + PRN groups. Additionally, visual stabilization was observed after a prolonged treatment period and regular anti-VEGF dosing, hinting that the
adoption of such protocol might help reduce the treatment burden. One of the major limitations of this study is its small number of participants and its relatively short follow-up period. PRN regimens are likely to be beneficial for patients with such conditions. However, future research should focus on larger controlled studies and long-term dosing strategies to confirm our data.

Conclusions
This observational study confirms that no significant differences in terms of anatomic or visual outcomes were noted between the 1 + PRN and the 3 + PRN groups. Therefore, three monthly injections might be more appropriate in some cases for the initial management of ME secondary to BRVO.

Abbreviations
BRVO: branch retinal vein occlusion; IVC: intravitreal injection of conbercept; ME: macular edema; PRN: pro re nata; BCVA: Best-corrected visual acuity; logMAR: Logarithm of minimum angle of resolution; CFT: central foveal thickness; OCT: Optical coherence tomography; FFA: fluorescein fundus angiography; ETDRS: The Early Treatment Diabetic Retinopathy Study; SD: Standard deviation

Declarations

Acknowledgments
None

Author Contributions
Xi Chen and Wei Wei planned and analyzed the study. Tianming Hu, Zehao Liu and Yaxin Zhan carried out the measurements. Xi Chen wrote the manuscript with support from Wei Wei and Jing Zuo. Jing Wang and Hao Wu helped supervise the project. All authors reviewed the manuscript.

Funding
This work was supported by grants from the National Natural Science Foundation of China (81774370).

Availability of data and materials
Not applicable.

Ethics approval and consent to participate
All performed procedures in this study were done according to the ethical standard of The Jiangsu
Province Hospital of Chinese Medicine and adhered to the 1964 Helsinki declaration and its latest amendments.

**Consent for publication**

Not applicable

**Competing interests**

The authors declare that they have no competing interests

**References**

1. Tah V, Orlans HO, Hyer J, et al. Anti-VEGF Therapy and the Retina: An Update. J Ophthalmol. 2015;2015:627674.

2. Rogers S, McIntosh RL, Cheung N, et al. The prevalence of retinal vein occlusion: pooled data from population studies from the United States, Europe, Asia, and Australia. Ophthalmology 2010;117(2).

3. Campochiaro PA, Brown DM, Awh CC, et al. Sustained benefits from ranibizumab for macular edema following central retinal vein occlusion: twelve-month outcomes of a phase III study. Ophthalmology. 2011;118(10):2041–9.

4. Vance SK, Chang LK, Imamura Y, Freund KB, et al. Effects of intravitreal anti-vascular endothelial growth factor treatment on retinal vasculature in retinal vein occlusion as determined by ultra wide-field fluorescein angiography. Retinal cases brief reports. 2011;5(4):343–7.

5. Campochiaro PA. Anti-vascular endothelial growth factor treatment for retinal vein occlusions. Ophthalmologica. Journal international d'ophtalmologie. International journal of ophthalmology. Zeitschrift fur Augenheilkunde 2012: 30 – 5.

6. Koss MJ, Pfister M, Rothweiler F, et al. Comparison of cytokine levels from undilated vitreous of untreated patients with retinal vein occlusion. Acta ophthalmologica. 2012;90(2):e98–103.

7. Campochiaro PA, Heier JS, Feiner L, et al. Ranibizumab for macular edema following
branch retinal vein occlusion: six-month primary end point results of a phase III study. Ophthalmology. 2010;117(6):1102–12.e1.

8. Leitritz MA, Gelisken F, Ziemssen F, et al. Grid laser photocoagulation for macular oedema due to branch retinal vein occlusion in the age of bevacizumab? Results of a prospective study with crossover design. Br J Ophthalmol. 2013;97(2):215–9.

9. Campochiaro PA, Clark WL, Boyer DS, et al. Intravitreal aflibercept for macular edema following branch retinal vein occlusion: the 24-week results of the VIBRANT study. Ophthalmology. 2015;122(3):538–44.

10. Wecker T, Ehlken C, Bühler A, et al. Five-year visual acuity outcomes and injection patterns in patients with pro-re-nata treatments for AMD, DME, RVO and myopic CNV. Br J Ophthalmol. 2017;101(3):353–9.

11. Miwa Y, Muraoka Y, Osaka R, et al RANIBIZUMAB FOR MACULAR EDEMA AFTER BRANCH RETINAL VEIN OCCLUSION. One Initial Injection Versus Three Monthly Injections. Retina (Philadelphia Pa). 2017;37(4):702–9.

12. Sun Z, Zhou H, Lin B, et al EFFICACY AND SAFETY OF INTRAVITREAL CONBERCEPT INJECTIONS IN MACULAR EDEMA SECONDARY TO RETINAL VEIN OCCLUSION. Retina (Philadelphia Pa). 2017;37(9):1723–30.

13. Osaka R, Muraoka Y, Miwa Y, et al. Anti-Vascular Endothelial Growth Factor Therapy for Macular Edema following Central Retinal Vein Occlusion: 1 Initial Injection versus 3 Monthly Injections. Ophthalmologica. Journal international d'ophtalmologie. International journal of ophthalmology Zeitschrift fur Augenheilkunde. 2018;239(1):27–35.

14. Singer M, Tan CS, Bell D, Sadda SR, et al. Area of peripheral retinal nonperfusion and treatment response in branch and central retinal vein occlusion. Retina (Philadelphia Pa). 2014;34(9):1736–42.
15. Tadayoni R, Waldstein SM, Boscia F, et al. Sustained Benefits of Ranibizumab with or without Laser in Branch Retinal Vein Occlusion: 24-Month Results of the BRIGHTER Study. Ophthalmology. 2017;124(12):1778–87.

16. Li F, Sun M, Guo J, et al. Comparison of Conbercept with Ranibizumab for the Treatment of Macular Edema Secondary to Branch Retinal Vein Occlusion. Curr Eye Res. 2017;42(8):1174–8.

Tables

Table 1. Baseline Characteristics of the Study Population.

|                | Total       | 1+PRN Group | 3+PRN Group | P       |
|----------------|-------------|-------------|-------------|---------|
| **Baseline**   |             |             |             |         |
| Number (patients/eyes) | 49/49       | 24/24       | 25/25       | NA      |
| Gender(Male/ Female)     | 21/28       | 12/12       | 9/16        | 0.322   |
| Age, years              | 56.12±12.54 | 56.71±14.2  | 55.56±10.98 | 0.752   |
| Diagnosis(non-ischemic/ischemic) | 30/19 | 11/10 | 11/9 | 0.858 |
| **Baseline**   |             |             |             |         |
| BCVA(LogMAR)    | 0.751±0.418 | 0.772±0.382 | 0.731±0.456 | 0.74    |
| CFT, µm        | 520.7±204.8 | 522.3±211.2 | 519.2±202.8 | 0.959   |
| **Final**      |             |             |             |         |
| BCVA(LogMAR)    | 0.424±0.298 | 0.464±0.285 | 0.386±0.311 | 0.362   |
| CFT, µm        | 295.3±78    | 301.8±98.9  | 289.1±52.2  | 0.575   |
| Number of injections during 12 mo | 4.4±1.5 | 4.0±1.7 | 4.6±1.2 | 0.155 |

PRN, pro re nata; BCVA, best-corrected visual acuity; LogMAR, the logarithm of the minimum angle of resolution; CFT, Central foveal thickness.

Continuous variables were presented as mean and SD. P-value <0.05 was considered statistically significant.

Figures
Changes in mean visual acuity (logMAR) and CFT in all treated eyes from baseline to month 12. The VA showed improvement from the baseline (0.751±0.418) to month 12 (0.424±0.298). Similarly, the results indicated a significant decrease in CFT from the baseline (520.7 μm±204.8 μm) to month 12 (295.3 μm±78 μm). # p<0.05, +p=0.001 and *p=0.001 compared with baseline values.
Changes in mean visual acuity (logMAR) and CFT from baseline to month 12. The results showed subsequent improvement in visual acuity with a rapid reduction in CFT after conbercept injections. Means VA were 0.308±0.431 in the 1+pro re nata (PRN) group and 0.345±0.366 in the 3+PRN group at baseline. The results also indicated a significant decrease in CFT (220.5 μm±219.9 μm for the 1+PRN group and 230.2 μm±220 μm for the 3+PRN group) after initiation of the treatment. The differences in CRT and VA between the two groups were not statistically significant (P>0.05).
Changes in mean visual acuity (logMAR) and CFT in the ischemic and non-ischemic subgroups from baseline to month 12. Mean VA gained from $0.735\pm0.365$ at baseline to $0.384\pm0.238$ at month 12 in the non-ischemic subgroup, and improved from $0.776\pm0.5$ at baseline to $0.487\pm0.373$ at month 12 in the ischemic subgroup ($p<0.001$ and $P=0.007$, respectively). Similarly, mean CFT reduced from $518.9\ \mu m\pm222.6\ \mu m$ at baseline to $292.3\ \mu m\pm82.2\ \mu m$ at month 12 in the non-ischemic subgroup, and $523.6\ \mu m\pm178.9\ \mu m$ at baseline to $300\ \mu m\pm72.9\ \mu m$ at month 12 in the ischemic subgroup ($p<0.001$).

Figure 4

Scatter plots showing the association between the number of PRN conbercept injections and the duration until the first PRN injection. The total number of PRN injections was significantly associated with shorter durations until initial PRN injection in both groups ($R = -0.489$, $P = 0.003$, $R = -0.452$, $P=0.008$, respectively).
